Antitumor Agent-114, a potent STING (stimulator of interferon genes) agonist, activates immune responses and diminishes tumor size in mouse breast cancer models, demonstrating potential applications in immunity and cancer research [1].

Antitumor agent-114 (compound 14c) was administered intrathecally at doses of 2, 0.67, and 0.22 mg/kg on days 1, 4, and 7, respectively, in a 4T1 tumor-bearing mouse model, resulting in complete tumor regression through systemic immune activation [1].